Sleep apnea affects over 1 billion people globally with 80% undiagnosed in the US. Traditional care involves long waits of months and lab visits, leading to poor adherence around 45% for CPAP.
Ognomy addresses this $10B+ market with virtual-first model that is 9x faster, 62% cheaper, and achieves 74% compliance. Recent $20M Series A positions it to scale nationally as sleep health integrates with cardiometabolic care.
Product Overview
Ognomy Sleep offers an end-to-end virtual platform for obstructive sleep apnea care. Patients complete an at-home FDA-cleared sleep test, receive virtual consultations with board-certified specialists, and access personalized treatment including PAP, oral appliances, Inspire therapy, and GLP-1 options.
The AI-enabled system handles scheduling, testing, diagnosis, treatment coordination and adherence support. It operates in all 50 states, accepts most insurance, offers self-pay, and achieves superior compliance and patient satisfaction.
